Clinical Research Directory
Browse clinical research sites, groups, and studies.
4 clinical studies listed.
Filters:
Tundra lists 4 Severe Renal Impairment clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07946068
Aleniglipron Renal Impairment Study
The purpose of this study is to evaluate the effect of severe RI on IHD on the PK of aleniglipron to establish scientifically guided dosing recommendations in these special patient populations.
Gender: All
Ages: 18 Years - 85 Years
Updated: 2026-11-18
1 state
NCT04119843
Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function
The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-10
18 states
NCT07840313
Prophylactic Desmopressin Before Native Kidney Biopsy in Severe Renal Impairment
This study evaluated whether giving desmopressin before a native kidney biopsy reduces bleeding complications in adults with severe renal impairment (eGFR \<30 mL/min/1.73 m²). Patients undergoing kidney biopsy were enrolled sequentially into two groups: a non-desmopressin group and a desmopressin group. Patients were monitored for 24 hours after biopsy for bleeding complications, including perinephric hematoma, a decrease in hemoglobin, blood in the urine, need for blood transfusion, and other complications. The study also evaluated whether desmopressin was associated with adverse effects such as low blood sodium levels.
Gender: All
Ages: 18 Years - 90 Years
Updated: 2026-09-25
1 state
NCT07734610
A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)
The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.
Gender: All
Ages: 18 Years - 80 Years
Updated: 2026-09-23
1 state